| Old Articles: <Older 7371-7380 Newer> |
|---|
 |
The Motley Fool
April 23, 2011 |
St. Jude, Medtronic Execs Offer Different Views on JAMA Article's Impact An article and government investigation into implant devices may or may not have played a role in each company's performance, depending on whom you ask.   |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
BusinessWeek
April 21, 2011
Tom Randall |
Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
April 21, 2011
Arlene Weintraub. |
5 Questions for IBM on Watson, Jeopardy, and Real-World Applications for Sophisticated Analytics Can IBM's Watson computer be useful in hospitals and emergency rooms? |
The Motley Fool
April 21, 2011
Luke Timmerman |
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis. |
The Motley Fool
April 21, 2011
Rex Moore |
Top 10 Values in Health Care Here are the 10 health care equipment and services stocks with the lowest forward price-to-earnings multiples. |
The Motley Fool
April 20, 2011
Charly Travers |
Are These the Rights You're Looking for? Consider the contingent value rights of these pharma stocks, which entitle the owner to receive cash payments if certain performance milestones are met in the future. |
| <Older 7371-7380 Newer> Return to current articles. |
